Iron metabolism and Parkinson's disease

Movement Disorders

Volumn 13, Issue SUPPL. 1, 1998, Pages 39-45

  Hirsch, Etienne C ^a   Faucheux, Baptiste A ^a  

^a PITIÉ SALPÊTRIÈRE HOSPITAL   (France)

Author keywords

Dopaminergic neurons; Lactoferrin; Neuronal death; Transferrin

Indexed keywords

FERRITIN; HYDROXYL RADICAL; LACTOFERRIN; TRANSFERRIN;

CONFERENCE PAPER; DOPAMINERGIC NERVE CELL; HUMAN; IRON BLOOD LEVEL; IRON METABOLISM; NERVE CELL NECROSIS; NONHUMAN; OXIDATIVE STRESS; PARKINSON DISEASE; PRIORITY JOURNAL; SUBSTANTIA NIGRA;

CELL DEATH; DOPAMINE; FREE RADICALS; HUMANS; HYDROXYL RADICAL; IRON; LACTOFERRIN; NEURONS; PARKINSON DISEASE; REACTIVE OXYGEN SPECIES; SUBSTANTIA NIGRA; TRANSFERRIN;

EID: 0031947244     PISSN: 08853185     EISSN: None     Source Type: Journal    
DOI: 10.1002/mds.870130111     Document Type: Conference Paper

References (55)

1. Hirsch EC, Graybiel AM, Agid Y. Melanized dopaminergic neurons are differentially susceptible to degeneration in Parkinson's disease. Nature 1988;334:345-348.
2. Hirsch EC. Does oxidative stress participate in nerve cell death in Parkinson's disease? Eur Neurol 1993;33:52-59.
3. Swartz HM, Sarna T, Zecca L. Modulation by neuromelanin of the availability and reactivity of metal ions. Ann Neurol 1992;32: S69-S75.
4. Halliwell B, Gutteridge JMC. Iron and free radical reactions: two aspects of antioxidant protection. Trends Biol Sci 1986;11:1372-1375.
5. Zhang P, Damier P, Hirsch EC, et al. Preferential expression of superoxide dismutase messenger RNA in melanized neurons in human mesencephalon. Neuroscience 1993;55:167-175.
6. Damier P, Hirsch EC, Zhang P, Agid Y, Javoy-Agid F. Glutathione peroxidase, glial cells and Parkinson's disease. Neuroscience 1993;52:1-6.
7. Donaldson J. The pathophysiology of trace metal: neurotransmitter interaction in the CNS. Trends Pharmacol Sci 1981;1:75-77.
8. Nagatsu T. Tyrosine hydroxylase: human isoforms, structure and regulation in physiology and pathology. Essays Biochem 1995;30: 15-35.
9. Schneiberg IH, Strenlieb L. Wilson's disease. Philadelphia, PA: WB Saunders, 1984.
10. Birchall JD, Chappell JD. Aluminum, chemical physiology and Alzheimer's disease. Lancet 1988;ii:1008-1010.
11. Barbeau A. Manganese and extrapyramidal disorders (a critical review and tribute to Dr. Georges C. Cotzias). Neurotoxicology 1984;5:13-36.
12. Earle KM. Studies on Parkinson's disease including x-ray fluorescent spectroscopy of formalin fixed brain tissue. J Neuropathol Exp Neurol 1968;27:1-14.
13. Dexter DT, Wells FR, Lees A, et al. Increased nigral iron content and alterations in other metal ions occurring in brain in Parkinson's disease. J Neurochem 1989;52:1830-1836.
14. Riederer P, Sofic EM, Rausch WD, et al. Transition metals, ferritin, glutathione and ascorbic acid in parkinsonian brains. J Neurochem 1989;52:515-520.
15. Jellinger K, Kienzl E, Rumpelmair G, et al. Iron-melanin complex in substantia nigra of parkinsonian brain: an x-ray microanalysis. J Neurochem 1992;59:1168-1171.
16. Jellinger K, Kienzl E, Paulus W, Riederer P, Rumpelmair H, Sofic E. Iron and ferritin in substantia nigra in Parkinson's disease. In: Narabayashi H, Nagatsu T, Yanagisawa N, Mizuno Y, eds. Parkinson's disease: From basic research to treatment. New York, NY: Raven Press, 1993:267-281.
17. Hirsch EC, Brandel JP, Galle P, Javoy-Agid F, Agid Y. Iron and aluminum increase in the substantia nigra of patients with Parkinson's disease. An x-ray microanalysis. J Neurochem 1991;56:446-451.
18. Good PF, Olanow CW, Perl DP. Neuromelanin-containing neurons of the substantia nigra accumulate iron and aluminum in Parkinson's disease: a LAMMA study. Brain Res 1992;593:343-346.
19. Gutteridge JM, Quilan GJ, Clark I, Halliwel B. Aluminum salts accelerate peroxidation of membrane lipids stimulated iron salts. Biochem Biophys Acta 1985;835:441-447.
20. Dexter DT, Carter CJ, Wells FR, et al. Basal lipid peroxidation in substantia nigra is increased in Parkinson's disease. J Neurochem 1989;52:381-389.
21. Levi S, Yewdall SJ, Harrison PM, et al. Evidence that H-L-chains have cooperative roles in the iron uptake mechanism of human ferritin. Biochem J 1992;288:591-596.
22. Santambrogio P, Levi S, Cozzi A, Rovida E, Albertini A, Arosio P. Production and characterization of recombinant heteropolymers of human ferritin H and L chains. J Biol Chem 1993;268:12744-12748.
23. Connor JR, Boeshore KL, Benkovic SA, Menzies SL. Isoforms of ferritin have a specific cellular distribution in the brain. J Neurosci Res 1994;37:461-465.
24. Balla G, Jacob HS, Rosenberg M, et al. Ferritin: a cytoprotective antioxidant stratagem of endothelium. J Biol Chem 1992;267: 18148-18153.
25. Dexter DT, Carayon A, Vidailhet M, et al. Decreased ferritin levels in the brain in Parkinson's disease. J Neurochem 1990;55:16-20.
26. Connor JR, Snyder BS, Arosio P, Loeffler DA, LeWitt P. A quantitative analysis of isoferritins in select regions of aged, parkinsonian, and Alzheimer's disease brains. J Neurochem 1995;65:717-724.
27. Aisen P. Entry of iron into cells: a new role for the transferrin receptor in modulating iron release from transferrin. Ann Neurol 1992;32:S62-S68.
28. Hill JM, Ruff MR, Weber RJ, Pert CB. Transferrin receptors in rat brain: neuropeptide-like pattern and relationship to iron distribution. Proc Natl Acad Sci USA 1985;82:4553-1557.
29. Mash DC, Pablo J, Flynn DD, Efange SMN, Weiner WJ. Characterization and distribution of transferrin receptors in the rat brain. J Neurochem 1990;55:1972-1979.
30. Morris CM, Candy JM, Bloxham CA, Edwardson JA. Distribution of transferrin receptors in relation to cytochrome oxidase activity in the human spinal cord, lower brainstem and cerebellum. J Neural Sci 1992;111:158-172.
31. Kalaria RN, Sromek SM, Grahovac I, Harik SI. Transferrin receptors of rat and human brain and cerebral microvessels and their status in Alzheimer's disease. Brain Res 1992;585:87-93.
32. Faucheux BA, Hirsch EC, Villares J, et al. Distribution of [125I]-ferrotransferrin binding sites in the mesencephalon of control subjects and patients with Parkinson's disease. J Neurochem 1993;60: 2338-2341.
33. Faucheux BA, Hauw JJ, Agid Y, Hirsch EC. The density of [125I]-transferrin binding sites on perikarya of melanized neurons of the substantia nigra is decreased in Parkinson's disease. Brain Res 1997;749:170-174.
34. Morris CM, Candy JM, Keith AB, et al. Brain iron homeostasis. J Inorg Biochem 1992;47:257-265.
35. Crowe A, Morgan EH. Iron and transferrin uptake by brain and cerebrospinal fluid in the rat. Brain Res 1992;592:8-16.
36. Fearnley JM, Lees A. Aging and Parkinson's disease: substantia nigra regional selectivity. Brain 1991;114:2283-2302.
37. Hoehn MM, Yahr MD. Parkinsonism: onset, progression and mortality. Neurology 1967;17:427-442.
38. Klausner RD, Rouault TA, Harford JB. Regulating the fate of mRNA: the control of cellular iron metabolism. Cell 1993;72:19-28.
39. Javoy-Agid F, Hirsch EC, Dumas S, Duyckaerts C, Mallet J, Agid Y. Decreased tyrosine hydroxylase mRNA in the surviving nigral dopamine neurons in Parkinson's disease: an in situ hybridization study. Neuroscience 1990;38:245-253.
40. Kastner A, Hirsch EC, Agid Y, Javoy-Agid F. Tyrosine hydroxylase protein and messenger RNA in the dopaminegic nigral neurons of patients with Parkinson's disease. Brain Res 1993;606: 341-345.
41. Kawamata T, Tooyama I, Yamada T, Walker DG, McGeer PL. Lactotransferrin immunohistochemistry in Alzheimer and normal human brains. Am J Pathol 1993;143:1574-1585.
42. Leveugle B, Spik G, Perl DP, Bouras C, Fillit HM, Hof PR. The iron binding protein lactotransferrin is present in pathologic lesions in a variety of neurodegenerative disorders: a comparative immunohistochemical analysis. Brain Res 1994;650:20-31.
43. Osmand AP, Switzer RC III. Differential distribution of lactoferrin and Alz-50 immunoreactivities in neuritic plaques and neurofibrillary tangles in Alzheimer's disease. In: Iqbal K, McLachlan RC, Winblad B, Wisniewski HM, eds. Alzheimer's disease: Basic mechanisms, diagnosis and therapeutic strategies. New York, NY: Wiley, 1991:219-227.
44. Rebeck GW, Harr SD, Strickland DK, Hyman BT. Multiple, diverse senile plaque-associated proteins are ligands of an alipoprotein E receptor, the alpha-macroglobulin receptor/low density lipoprotein receptor-related protein. Ann Neurol 1995;37:211-217.
45. Mazurier J, Spik G. Comparative study of the iron-binding properties of human transferrins. Complete and sequential iron saturation and desaturation of the lactotransferrin. Biochim Biophys Acta 1980;629:399-408.
46. Hu WL, Mazurier J, Sawatzki G, Montreuil J, Spik G. Lactotransferrin receptor of mouse small intestinal brush border. Biochem J 1988;249:435-441.
47. Migokami T, Heyman M, Spik G, Desjeux JF. Apical-to-basolateral transepithelial transport of human lactoferrin in the intestinal cell line HT-29 cl.19A. Am J Physiol 1994;267: G308-G315.
48. Rochard E, Legrand D, Lecocq D, et al. Characterization of lactotransferrin receptor in epithelial cell lines from nonmalignant human breast, benign mastopathies and breast carcinomas. Anticancer Res 1992;12:2047-2051.
49. Leveugle B, Mazurier J, Legrand D, Mazurier C, Montreuil J, Spik G. Lactotranferrin binding to its platelet receptor inhibits platelet aggregation. Eur J Biochem 1993;213:1205-1211.
50. Faucheux BA, Nillesse N, Damier P, et al. Expression of lactoferrin receptors is increased in the mesencephalon of patients with Parkinson's disease. Proc Natl Acad Sci USA 1995;92:9603-9607.
51. Leveugle B, Faucheux BA, Bouras C, et al. Immunohistochemical analysis of the iron-binding protein lactotransferrin in the mesencephalon of Parkinson's disease cases. Acta Neuropathol 1996;91: 566-572.
52. Connor JR, Boeshore KL, Benkovic SA, Menzies SL. Isoforms of ferritin have a specific cellular distribution in the brain. J Neurosci Res 1994;37:461-465.
53. Leenders KL, Antonini A, Pellikar R. Brain iron uptake in patients with Parkinson's disease measured using (52Fe)-citrate and positron emission tomography. 11th International Symposium on Parkinson's disease; Rome, Italy; March 26-30, 1994.
54. Jenner P. Oxidative damage in neurodegenerative disease. Lancet 1994;344:796-798.
55. Mochizuki H, Ima H, Endo K, et al. Iron accumulation in the substantia nigra of 1-methyl-phenyl-1,2,3,6-tetrahydroxypyridine (MPTP)-induced hemiparkinsonian monkeys. Neurosci Lett 1994; 168:251-253.